On December 21, 2022, the New Zealand Medicinal Cannabis Agency announced the verification of two new medicinal cannabis products containing tetrahydrocannabinol (THC) that meet quality standards.
A week ago, Helius became New Zealand's first company to be GMP certified, allowing them to produce THC extracts and manufacture THC-containing medications.
Carmen Doran, CEO of Helius, stated, "We are delighted to bring more medicinal cannabis products grown and manufactured in New Zealand to patients in the country.
Helius will have a total of six drugs in its product portfolio in 2022, as two new drugs have entered the New Zealand market. This brings their total of new drugs to four.
In mid-December, we were able to announce GACP certification, and since then, we have also received GMP certification for four additional processes at our factory in the East Auckland area. This progress demonstrates the strength of the Helius team," she said.
Helius is the only company in New Zealand that has obtained Good Manufacturing Practice (GMP) certification for the extraction and production of CBD and THC medications. Even more importantly, it is one of only two companies in the country that currently has six products validated to meet the minimum quality standards (the other being Nubu Pharma).
Helius' latest product will be exported to European clients in 2023.
The products containing THC have attracted great interest internationally, and with the continued growth of the medical market, globally manufactured GMP products have received widespread attention. We have found that people are particularly interested in balanced full-spectrum medicinal cannabis formulas," said Ms. Doran.
With the launch of these products, New Zealand patients can now use a variety of locally manufactured oral liquid products. They no longer have to rely on imported products that may experience supply delays throughout 2022 and potentially be much more expensive.
The newly approved drug was developed at Helius' large manufacturing facility. Cannabinoids are active compounds found in the cannabis plant, which are also extracted from dried flowers grown at the Helius factory, allowing them to produce plant-based solutions for patients under one roof.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
